Trevena has been awarded a $7.65m Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). The grant will further fund Trevena’s work to identify and characterise functionally selective biased ligands for a wide range of GPCRs.
The grant will also enable the company to make tool molecules available to research collaborators to accelerate and expand the role of key signaling pathways in biological processes.
Maxine Gowen, president and CEO of Trevena, said: “Trevena is discovering and developing the next generation of GPCR-targeted drugs. Unlike previous GPCR therapies, our proprietary approach enables us to identify biased ligands for individual GPCRs and discover and develop highly differentiated drugs that can precisely activate selective signaling pathways.
“This grant supports not only Trevena’s work in identifying and characterising biased ligands for important GPCRs, but enables us to share these findings with researchers in the field to advance the understanding of GPCR biology. We are extremely excited about this prospect and look forward to these collaborations.”